BIOMAT Database Logo BIOMAT Database Logo

Cyproheptadine in the treatment of Nelson's syndrome. 1979

W Hartwig, and A Kasperlik-Załuska, and J Wilczyńska, and B Migdalska, and K Czechowicz-Janicka, and J Załuska

UI MeSH Term Description Entries
D009347 Nelson Syndrome A syndrome characterized by HYPERPIGMENTATION, enlarging pituitary mass, visual defects secondary to compression of the OPTIC CHIASM, and elevated serum ACTH. It is caused by the expansion of an underlying ACTH-SECRETING PITUITARY ADENOMA that grows in the absence of feedback inhibition by adrenal CORTICOSTEROIDS, usually after ADRENALECTOMY.
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D003533 Cyproheptadine A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. Antergan,Dihexazin,Periactin,Peritol,Viternum
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

W Hartwig, and A Kasperlik-Załuska, and J Wilczyńska, and B Migdalska, and K Czechowicz-Janicka, and J Załuska
Cyproheptadine in Nelson's syndrome.
August 1976, Lancet (London, England),
W Hartwig, and A Kasperlik-Załuska, and J Wilczyńska, and B Migdalska, and K Czechowicz-Janicka, and J Załuska
Sustained remission of Nelson's syndrome after stopping cyproheptadine treatment.
February 1980, The New England journal of medicine,
W Hartwig, and A Kasperlik-Załuska, and J Wilczyńska, and B Migdalska, and K Czechowicz-Janicka, and J Załuska
Cyproheptadine therapy in Cushing's disease and Nelson's syndrome.
March 1980, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
W Hartwig, and A Kasperlik-Załuska, and J Wilczyńska, and B Migdalska, and K Czechowicz-Janicka, and J Załuska
Effectiveness of cyproheptadine in decreasing plasma ACTH concentrations in Nelson's syndrome.
November 1976, The Journal of clinical endocrinology and metabolism,
W Hartwig, and A Kasperlik-Załuska, and J Wilczyńska, and B Migdalska, and K Czechowicz-Janicka, and J Załuska
Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.
January 2004, Hormone research,
W Hartwig, and A Kasperlik-Załuska, and J Wilczyńska, and B Migdalska, and K Czechowicz-Janicka, and J Załuska
Cyproheptadine treatment of Nelson's syndrome: restoration of plasma ACTH circadian periodicity and reversal of response to TRF.
February 1978, The Journal of clinical endocrinology and metabolism,
W Hartwig, and A Kasperlik-Załuska, and J Wilczyńska, and B Migdalska, and K Czechowicz-Janicka, and J Załuska
Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome.
February 1997, The Journal of clinical endocrinology and metabolism,
W Hartwig, and A Kasperlik-Załuska, and J Wilczyńska, and B Migdalska, and K Czechowicz-Janicka, and J Załuska
Microsurgical treatment of Nelson's syndrome.
August 2002, Chinese medical journal,
W Hartwig, and A Kasperlik-Załuska, and J Wilczyńska, and B Migdalska, and K Czechowicz-Janicka, and J Załuska
Neurosurgical treatment of Nelson's syndrome.
December 2002, The Journal of clinical endocrinology and metabolism,
W Hartwig, and A Kasperlik-Załuska, and J Wilczyńska, and B Migdalska, and K Czechowicz-Janicka, and J Załuska
Treatment of Nelson's syndrome with temozolomide.
January 2009, European journal of endocrinology,
Copied contents to your clipboard!